D-0295-2019 Class III Terminated

Recalled by QuVa Pharma, Inc. — Sugar Land, TX

FDA drug recall D-0295-2019 was initiated by QuVa Pharma, Inc. on Nov 21, 2018 and is designated Class III. Reason for recall: Incorrect excipient: Product was compounded in 250 mL 5% Dextrose instead of 250 mL 0.9% Sodium Chloride The recall status is terminated (terminated May 1, 2019). Affected quantity: 168 bags.

Recall details

Product Type
Drugs
Report Date
Dec 19, 2018
Initiation Date
Nov 21, 2018
Termination Date
May 1, 2019
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
168 bags

Product description

Norepinephrine 8 mg (32 mcg/mL) added to 0.9% Sodium Chloride Injection 250 mL Bag, Rx only, Compounded by: QuVA Pharma 1075 West Park One Drive Suite 100 Sugar Land, TX 77478. Product Code 70092-9035-05

Reason for recall

Incorrect excipient: Product was compounded in 250 mL 5% Dextrose instead of 250 mL 0.9% Sodium Chloride

Distribution pattern

CA only

Code information

Lot #:10016014 Exp. 01/06/2019

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0295-2019
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0295-2019. Report a data issue: hello@regdatalab.com.